This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -109.09% and 11.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -16.67% and 28.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 18.75% and 95.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -5.00% and 260.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter
by Zacks Equity Research
The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
by Zacks Equity Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Why Liquidia Technologies (LQDA) Stock Might be a Great Pick?
by Zacks Equity Research
Liquidia Technologies (LQDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Liquidia Technologies, Inc. (LQDA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Liquidia Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Liquidia.
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.